A flow-cytometry-based pipeline for the rapid quantification of C2C12 cell differentiation

  • STAR Protoc. 2023 Oct 10;4(4):102637. doi: 10.1016/j.xpro.2023.102637.
Bianca Parisi  1 ,  Maxime Sünnen  1 ,  Rohan Chippalkatti  2 ,  Daniel Kwaku Abankwa  3
Affiliations
  • 1. Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg.
  • 2. Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg. Electronic address: [email protected].
  • 3. Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg. Electronic address: [email protected].
PMID: 37819762 DOI: 10.1016/j.xpro.2023.102637
Abstract

The C2C12 cell line represents a simple in vitro model for cell differentiation. Here, we present a flow-cytometry-based pipeline to quantitate C2C12 cell differentiation based on Myosin heavy-chain marker expression. We describe steps for cell seeding, transfection, drug treatment, differentiation, and labeling. We then detail procedures for flow cytometry acquisition and introduce the R script FlowFate for automated analysis, including the study of dose-dependent effects of GFP-tagged genes on differentiation. For complete details on the use and execution of this protocol, please refer to Chippalkatti et al. (2023).1.

Keywords
Cancer; Cell Biology; Molecular Biology.
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-114277
    Sotorasib
    99.70%, KRAS G12C Inhibitor
    target: Ras
    Research Areas: Cancer